How were SteadyMed's earnings last quarter?

SteadyMed Ltd. (NASDAQ:STDY) announced its earnings results on Tuesday, August, 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.17.

What other stocks do shareholders of SteadyMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SteadyMed investors own include Amicus Therapeutics (FOLD) , Fate Therapeutics (FATE) , Madrigal Pharmaceuticals (MDGL) , Neurocrine Biosciences (NBIX) , Rigel Pharmaceuticals (RIGL) , Supernus Pharmaceuticals (SUPN) , Verastem (VSTM) and Biocept (BIOC) .

When did SteadyMed IPO?

SteadyMed (STDY) raised $56 million in an IPO on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

NASDAQ:STDY

SteadyMed (STDY) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free STDY Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $4.73
▼
$4.73
50-Day Range: N/A
52-Week Range: $2.60
▼
$6.45

Volume: 160 shs
Average Volume: 85,138 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get SteadyMed alerts:

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About SteadyMed

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

STDY Stock News Headlines

December 20, 2023 | washingtonpost.com

Apes may remember old friends and family decades later, study says

December 18, 2023 | bbc.com

Social media effect 'tiny' in teenagers, large study finds

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

November 14, 2023 | usatoday.com

Should we clean up the trash in our oceans? New study has a controversial answer.

October 24, 2023 | usatoday.com

'Climate captives': Frogs, salamanders and toads dying rapidly as Earth warms, study says

October 3, 2023 | forbes.com

Fluoride And IQ? What Is The Link, What This Study Says

September 3, 2023 | foxnews.com

Babies, young child exposed to more screen time linked with developmental delays: Study

August 28, 2023 | marketwatch.com

Cost of Owning a Dog in Every State (2023 Study)

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

August 23, 2023 | foxnews.com

More younger people are receiving cancer diagnoses, study finds — especially this type

July 8, 2023 | usatoday.com

Climate change fueled California's recent surge in catastrophic wildfire seasons, study says

June 19, 2023 | usatoday.com

Study reveals how alcohol has heart benefits. Why you should still sip with caution.

June 10, 2023 | usatoday.com

The sixth extinction is underway, study finds. But here's why all hope is not lost.

June 2, 2023 | forbes.com

Best Bar Exam Study Loans Of June 2023

June 2, 2023 | usatoday.com

Study identifies symptoms that distinguish long COVID ‒ an essential step toward much-needed treatment

May 15, 2023 | forbes.com

Miss USA And Miss America Winners’ Home States May See Increase In Body Image Issues, Study Shows

May 11, 2023 | bbc.co.uk

Go The Distance: Study Skills

May 11, 2023 | marketwatch.com

Wearable Injectors Market Research Provided SOWT Analysis [Latest Report] (2023-2030)

May 9, 2023 | dailymail.co.uk

Face masks may raise risk of stillbirths, testicular issues and cognitive decline, study says

May 7, 2023 | usnews.com

Acad of Entre Stdy@Louverture

March 27, 2023 | marketwatch.com

Wearable Injectors Market Size and Forecast till 2030

March 24, 2023 | marketwatch.com

Wearable Injectors Market Major Players, Anlysis and Forecast till 2031

March 20, 2023 | foxnews.com

'Dad jokes' help kids develop into healthy adults: study

March 17, 2023 | nypost.com

study says

March 17, 2023 | marketwatch.com

Subcutaneous Infusion Systems Market Key Players and Forecast till 2028

March 12, 2023 | marketwatch.com

Global On-body Injectors Market Scenario Highlighting Key Drivers And Latest Trends 2023 – 2030 By VMReports

March 10, 2023 | marketwatch.com

Intravenous-to-Subcutaneous Drugs Market Competitive Strategy, Trend Analysis and Forecast till 2029

See More Headlines

Receive STDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SteadyMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2018
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:STDY
CUSIP: N/A
CIK: 1619087
Web: www.steadymed.com
Phone: 925-272-4999
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Jonathan M. N. Rigby (Age 50)
Pres, CEO & Director
Mr. David W. Nassif (Age 64)
Exec. VP & CFO
Mr. Robert Zwolinski
Sr. VP of Operations
Ms. Marylyn Rigby
Sr. Director of Investor Relations and Marketing
Mr. Carl Hicks Jr.
Editor & Chief of Bephenomental.com

Key Competitors

View All Competitors

STDY Stock Analysis - Frequently Asked Questions

How were SteadyMed's earnings last quarter?: SteadyMed Ltd. (NASDAQ:STDY) announced its earnings results on Tuesday, August, 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.17.
What other stocks do shareholders of SteadyMed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SteadyMed investors own include Amicus Therapeutics (FOLD), Fate Therapeutics (FATE), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Rigel Pharmaceuticals (RIGL), Supernus Pharmaceuticals (SUPN), Verastem (VSTM) and Biocept (BIOC).
When did SteadyMed IPO?: SteadyMed (STDY) raised $56 million in an IPO on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

This page (NASDAQ:STDY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SteadyMed (STDY) Stock Price, News & Analysis

About SteadyMed

STDY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

STDY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info